Broad betacoronavirus neutralization by a stem helix–specific human antibody

Dora Pinto(Vir Biotechnology (Switzerland)), Maximilian M. Sauer(University of Washington), Nadine Czudnochowski(VIR Biotechnology (United States)), Jun Siong Low(Università della Svizzera italiana), M. Alejandra Tortorici(University of Washington), Michael P. Housley(VIR Biotechnology (United States)), Julia Noack(VIR Biotechnology (United States)), Alexandra C. Walls(University of Washington), John E. Bowen(University of Washington), Barbara Guarino(Vir Biotechnology (Switzerland)), Laura E. Rosen(VIR Biotechnology (United States)), Julia di Iulio(VIR Biotechnology (United States)), Josipa Jerak(Università della Svizzera italiana), Hannah Kaiser(VIR Biotechnology (United States)), Saiful Islam(VIR Biotechnology (United States)), Stefano Jaconi(Vir Biotechnology (Switzerland)), Nicole Sprugasci(Vir Biotechnology (Switzerland)), Katja Culap(Vir Biotechnology (Switzerland)), Rana Abdelnabi(Rega Institute for Medical Research), Caroline S. Foo(Rega Institute for Medical Research), Lotte Coelmont(Rega Institute for Medical Research), István Bartha(Vir Biotechnology (Switzerland)), Siro Bianchi(Vir Biotechnology (Switzerland)), Chiara Silacci-Fregni(Vir Biotechnology (Switzerland)), Jessica Bassi(Vir Biotechnology (Switzerland)), Roberta Marzi(Vir Biotechnology (Switzerland)), Eneida Vetti(Vir Biotechnology (Switzerland)), Antonino Cassotta(Università della Svizzera italiana), Alessandro Ceschi(Ente Ospedaliero Cantonale), Paolo Ferrari(UNSW Sydney), Pietro E. Cippà(University of Zurich), Olivier Giannini(Ente Ospedaliero Cantonale), Samuele Ceruti(Clinica Luganese Moncucco), Christian Garzoni(Clinica Luganese Moncucco), Agostino Riva(Luigi Sacco Hospital), Fabio Benigni(Vir Biotechnology (Switzerland)), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), Luca Piccoli(Vir Biotechnology (Switzerland)), Matteo Samuele Pizzuto(Vir Biotechnology (Switzerland)), Megan J. Smithey(VIR Biotechnology (United States)), David K. Hong(VIR Biotechnology (United States)), Amalio Telenti(VIR Biotechnology (United States)), Florian A. Lempp(VIR Biotechnology (United States)), Johan Neyts(Rega Institute for Medical Research), Colin Havenar‐Daughton(VIR Biotechnology (United States)), Antonio Lanzavecchia(Vir Biotechnology (Switzerland)), Federica Sallusto(ETH Zurich), Gyorgy Snell(VIR Biotechnology (United States)), Herbert W. Virgin(Washington University in St. Louis), Martina Beltramello(Vir Biotechnology (Switzerland)), Davide Corti(Vir Biotechnology (Switzerland)), David Veesler(University of Washington)
Science
August 3, 2021
Cited by 430Open Access
Full Text

Abstract

The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus countermeasures. We describe five monoclonal antibodies (mAbs) cross-reacting with the stem helix of multiple betacoronavirus spike glycoproteins isolated from COVID-19 convalescent individuals. Using structural and functional studies, we show that the mAb with the greatest breadth (S2P6) neutralizes pseudotyped viruses from three different subgenera through the inhibition of membrane fusion, and we delineate the molecular basis for its cross-reactivity. S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 through viral neutralization and Fc-mediated effector functions. Stem helix antibodies are rare, oftentimes of narrow specificity, and can acquire neutralization breadth through somatic mutations. These data provide a framework for structure-guided design of pan-betacoronavirus vaccines eliciting broad protection.


Related Papers

No related papers found

Powered by citation graph analysis